Topical Ocular Compositions That Stimulate Tear Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for dry eye disorders, such as artificial tears, punctal plugs, and topical anti-inflammatory drugs, are inadequate in increasing tear production, leading to persistent symptoms and inflammation.
Innovation Solution
Topical administration of pharmaceutical compositions containing specific active agents, such as compounds of Formulas (I), (II), (III), (IV), or their pharmaceutically acceptable salts, in amounts of 5 micrograms or more, to increase tear production and treat dry eye disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatment options (artificial tears, punctal plugs, topical anti-inflammatory drugs) are used, then dry eye symptoms are managed to some extent, but tear production is not sufficiently increased
Solution Approach 1:
The patent changes the pharmacological parameter by introducing pro-secretory agents that directly stimulate tear production through specific receptors (muscarinic, adrenergic, cholinergic), thereby increasing tear volume and improving treatment effectiveness for dry eye disease
Solution Approach 2:
The patent uses intermediary substances (pro-secretory agents such as pilocarpine, cevimeline, and other compounds) that mediate between the administration route and the lacrimal glands to stimulate tear secretion, thereby resolving the contradiction between current treatment limitations and the need for increased tear production
2Quantity of substance
If tear fluid volume is increased, then tear fluid hyperosmolality is reduced, but the mechanism requires specific pro-secretory therapy
Solution Approach 1:
The patent changes the physiological parameter of tear fluid volume by administering pro-secretory agents that stimulate the lacrimal glands, thereby increasing tear fluid volume and reducing hyperosmolality through a well-defined pharmacological mechanism
3Productivity
If topical administration of active agents is used, then tear production is increased, but precise dosing control is required
Solution Approach 1:
The patent specifies precise dosing parameters (about 5 micrograms or more of active agent) to achieve the desired therapeutic effect while minimizing side effects, thereby resolving the contradiction between enhancing tear production and maintaining dosing accuracy
Solution Approach 2:
The patent employs a threshold dosing strategy where administering about 5 micrograms or more of the active agent ensures sufficient therapeutic effect while providing a clear dosing guideline that simplifies precision requirements
Data Source
AI summary
The disclosure provides, inter alia, topical pharmaceutical compositions comprising active agents, methods for increasing tear production using the topical pharmaceutical compositions, and methods for treating dry eye disorders using the topical pharmaceutical compositions.